1.The Efficacy of ZD1839 (Iressa(TM)) in Patients with Advanced Non- small Cell Lung Cancer which has Progressed After Previous Chemotherapy.
Seung Whan LEE ; Duck Ryung KIM ; Sang Dae LEE ; Jong Sin LEE ; Yeon Hee PARK ; Baek Yeol RYOO ; Heung Tae KIM ; Sunhoo PARK ; Bong Seog KIM ; Cheol Hyeon KIM ; Jae Cheol LEE
Tuberculosis and Respiratory Diseases 2004;57(2):160-167
BACKGROUND: The role of second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) is known to be limited. Recently, ZD1839, the small molecule epidermal growth factor receptor-tyrosine kinase inhibitor, has been developed and has shown anti-tumor activity in patients with solid malignant tumors including lung cancer. We evaluated the response rate and toxicities of ZD1839 in patients with advanced NSCLC which has progressed after previous chemotherapy. PATIENTS AND METHODS: We examined 83 patients with advanced NSCLC treated with ZD1839 for more than 1 month in Korea Cancer Center Hospital during the period from January 2002 to September 2003. All the patients were enrolled in the international expanded access program (EAP) with ZD1839 by AstraZeneca. The administered dose of ZD1839 was 250 mg once daily. Chest radiography and laboratory tests were followed-up. We evaluated the response rate, median survival, and toxicity after treatment. RESULTS: Median age of the patients was 59 years (range 33-76). The most predominant cell type was adenocarcinoma and the most stage of the patients was IV. ECOG performance status was as follows; grade 0-1 in 10, grade 2 in 42, and grade 3 in 31 patients. Partial response was achieved in 12 patients (14.5%). Median overall survival was 9.2 (range 1.3-21.6+) months and median time to progression was 3.1 (range 1-21.2+) months. The most common adverse effect of ZD1839 was skin eruption which developed in 25 patients (25.8%). Significantly higher response rate and survival was found in patients with adenocarcinoma or good performance status. CONCLUSION: ZD1839 showed modest activity and tolerable toxicity in the treatment for patients with NSCLC which has progressed after previous chemotherapy.
Adenocarcinoma
;
Carcinoma, Non-Small-Cell Lung
;
Drug Therapy*
;
Epidermal Growth Factor
;
Humans
;
Korea
;
Lung Neoplasms
;
Phosphotransferases
;
Radiography
;
Skin
;
Small Cell Lung Carcinoma*
;
Thorax
2.Dual-Energy CT in Patients Treated with Anti-Angiogenic Agents for Non-Small Cell Lung Cancer: New Method of Monitoring Tumor Response?.
Yoo Na KIM ; Ho Yun LEE ; Kyung Soo LEE ; Joon Beom SEO ; Myung Jin CHUNG ; Myung Ju AHN ; Keunchil PARK ; Tae Sung KIM ; Chin A YI
Korean Journal of Radiology 2012;13(6):702-710
OBJECTIVE: To evaluate tumor responses in patients treated with anti-angiogenic agents for non-small cell lung cancer (NSCLC) by assessing intratumoral changes using a dual-energy CT (DECT) (based on Choi's criteria) and to compare it to traditional Response Evaluation Criteria in Solid Tumors (RECIST) criteria. MATERIALS AND METHODS: Ten NSCLC patients treated with bevacizumab underwent DECT. Tumor responses to anti-angiogenic therapy were assessed and compared with the baseline CT results using both RECIST (size changes only) and Choi's criteria (reflecting net tumor enhancement). Kappa statistics was used to evaluate agreements between tumor responses assessed by RECIST and Choi's criteria. RESULTS: The weighted kappa value for the comparison of tumor responses between the RECIST and Choi's criteria was 0.72. Of 31 target lesions (21 solid nodules, 8 lymph nodes, and two ground-glass opacity nodules [GGNs]), five lesions (16%) showed discordant responses between RECIST and Choi's criteria. Iodine-enhanced images allowed for a distinction between tumor enhancement and hemorrhagic response (detected in 14% [4 of 29, excluding GGNs] of target lesions on virtual nonenhanced images). CONCLUSION: DECT may serve as a useful tool for response evaluation after anti-angiogenic treatment in NSCLC patients by providing information on the net enhancement of target lesions without obtaining non-enhanced images.
Adult
;
Aged
;
Angiogenesis Inhibitors/*therapeutic use
;
Antibodies, Monoclonal, Humanized/*therapeutic use
;
Carcinoma, Non-Small-Cell Lung/drug therapy/*radiography
;
Female
;
Humans
;
Image Processing, Computer-Assisted
;
Lung Neoplasms/drug therapy/*radiography
;
Male
;
Middle Aged
;
*Tomography, X-Ray Computed
3.Secondary Prophylaxis of Docetaxel Induced Diarrhea with Loperamide: Case Report.
Hee Yeon LEE ; Youn Hee LEE ; Min Ji KIM ; Hoon Kyo KIM
Journal of Korean Medical Science 2013;28(10):1549-1551
Diarrhea is a common adverse event of docetaxel with 20%-40% of incidence and severe diarrhea occurs in 5%-6%. Several treatment guidelines for chemotherapy induced diarrhea (CID) exist, however the prophylaxis for that is not well known. We describe a new prophylactic approach for the CID with loperamide. A 72-yr-old male patient with stage IV non-small-cell lung cancer developed diarrhea repeatedly after docetaxel-cisplatin chemotherapy. His diarrhea persisted despite treatment including loperamide and fasting. However, the diarrhea was successfully prevented when loperamide was given before and after the chemotherapy. To our knowledge, this is the first report of prophylactic approach for the CID with loperamide.
Aged
;
Carcinoma, Non-Small-Cell Lung/*drug therapy/radiography
;
Cisplatin/therapeutic use
;
Diarrhea/chemically induced/*etiology
;
Drug Therapy, Combination
;
Humans
;
Loperamide/*adverse effects/therapeutic use
;
Lung Neoplasms/*drug therapy/radiography
;
Male
;
Neoplasm Staging
;
Taxoids/*adverse effects/therapeutic use
;
Tomography, X-Ray Computed
4.Molecularly Targeted Therapy Using Bevacizumab for Non-Small Cell Lung Cancer: a Pilot Study for the New CT Response Criteria.
Ho Yun LEE ; Kyung Soo LEE ; Hye Sun HWANG ; Ju Won LEE ; Myung Ju AHN ; Keunchil PARK ; Tae Sung KIM ; Chin A YI ; Myung Jin CHUNG
Korean Journal of Radiology 2010;11(6):618-626
OBJECTIVE: We wanted to compare the efficacy of the new CT response evaluation criteria for predicting the tumor progression-free survival (PFS) with that of RECIST 1.1 in non-small cell lung cancer (NSCLC) patients who were treated with bevacizumab. MATERIALS AND METHODS: Sixteen patients (M:F = 11:5; median age, 57 years) treated with bevacizumab and combined cytotoxic chemotherapeutic agents were selected for a retrospective analysis. The tumor response was assessed by four different methods, namely, by using RECIST 1.1 (RECIST), RECIST but measuring only the solid component of tumor (RECISTsolid), the alternative method reflecting tumor cavitation (the alternative method) and the combined criteria (the combined criteria) that evaluated both the changes of tumor size and attenuation. To evaluate the capabilities of the different measurement methods to predict the patient prognosis, the PFS were compared, using the log rank test, among the responder groups (complete response [CR], partial response [PR], stable disease [SD] and progressive disease [PD]) in terms of the four different methods. RESULTS: The overall (CR, PR or SD) response rates according to RECIST, RECISTsolid, the alternative method and the combined criteria were 81%, 88%, 81% and 85%, respectively. The confirmed response rates (CR or PR) were 19%, 19%, 50% and 54%, respectively. Although statistically not significant, the alternative method showed the biggest difference for predicting PFS among the three response groups (PR, SD and PD) (p = 0.07). RECIST and the alternative method showed a significant difference for predicting the prognosis between the good (PR or SD) and poor overall responders (p = 0.02). CONCLUSION: The response outcome evaluations using the three different CT response criteria that reflect tumor cavitation, the ground-glass opacity component and the attenuation changes in NSCLC patients treated with bevacizumab showed different results from that with using the traditional RECIST method.
Angiogenesis Inhibitors/*therapeutic use
;
Antibodies, Monoclonal/*therapeutic use
;
Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/*radiography
;
Disease Progression
;
Female
;
Humans
;
Lung Neoplasms/*drug therapy/pathology/*radiography
;
Male
;
Middle Aged
;
Pilot Projects
;
Prognosis
;
Radiographic Image Interpretation, Computer-Assisted
;
Retrospective Studies
;
Salvage Therapy
;
Survival Rate
;
*Tomography, X-Ray Computed
;
Treatment Outcome
5.Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer.
Yun Hong CHEON ; Moon Jin KIM ; Min Gyu KANG ; Hee Jin KIM ; Sang Su LEE ; Cha Young KIM ; Dae Hong JEON ; Yu Eun KIM ; Gyeong Won LEE
Yonsei Medical Journal 2011;52(4):695-698
Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.
Aged
;
Antineoplastic Agents/*adverse effects/therapeutic use
;
Carcinoma, Non-Small-Cell Lung/complications/*drug therapy
;
Female
;
Humans
;
Intestinal Fistula/*chemically induced/complications/radiography/surgery
;
Intestinal Perforation/*chemically induced/complications/radiography/surgery
;
Protein Kinase Inhibitors/*adverse effects/therapeutic use
;
Quinazolines/*adverse effects/therapeutic use
;
Sigmoid Diseases/*chemically induced/complications/radiography/surgery